RPRX

About Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock

Royalty Pharma plc Class A Ordinary Shares (RPRX) closed the 2026-09-18 session at $58.41, down 0.88% versus the previous close (-0.52). The stock opened at $58.63 and traded between $57.97 and $58.96 during that session. Session trading volume was 7.1M shares. The volume-weighted average price (VWAP) is $58.39.

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Royalty Pharma plc Class A Ordinary Shares has a market capitalization of $26.01 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RPRX is listed on the XNAS exchange. The company employs approximately 100 people. Royalty Pharma plc Class A Ordinary Shares is headquartered in NEW YORK, NY. The recorded listing date is 2020-06-16.

On this page you can find market RPRX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.